All posts

Chango sale price suggests AcuityAds is undervalued, says Paradigm

The selling price of one of AcuityAds (AcuityAds Stock Quote, Chart, News: TSXV:AT) key comparables suggests it is undervalued, says Paradigm Capital analyst Spencer Churchill.

Yesterday, Toronto-based programmatic ad player Chango was acquired by Playa Vista, California-based digital advertising company Rubicon Project (NYSE: RUBI) in a deal valued at (U.S.) $122 million in cash and stock (approximately (C)$155-million).

“Chango’s technology brings keyword, contextual targeting and retargeting to premium display, mobile and video advertising. This will enable us to bring intent marketing budgets to an independent, open marketplace that serves premium buyers and sellers at scale for the first time,” explained Rubicon CEO Frank Addante.

Churchill says the valuation was done at 3x Chango’s trailing revenue number of an estimated (U.S.) $47-49-million. He thinks this valuation makes Acuity, which he describes as “very similar” to Chango, look cheap by comparison.

“With AcuityAds trading at 1.7x trailing and 1.3x forward revenue, the take-out valuation for Chango reinforces our view that AcuityAds is undervalued at current levels. Consolidation in the AdTech market continues at a very fast pace, and we believe this is the eventual end game for AcuityAds as its scale its business,” said Churchill.

In a research update to clients this morning, Churchill maintained his “Speculative Buy” rating and $1.80 target price on AcuityAds, implying a return of 82% at the time of publication.

Tagged with: at
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Small cap stocks are still cheap, this investor says

Nationwide’s chief market strategist Mark Hackett told CNBC’s Worldwide Exchange on Dec. 3 that survey data may look weak, but… [Read More]

2 days ago

Microbot Medical is a buy, Roth says

Roth Capital Markets initiated coverage of Microbot Medical (Microbot Medical Stock Quote, Chart, News, Analysts, Financials NASDAQ:MBOT) with a “Buy”… [Read More]

2 days ago

Texas could be big for these pot stocks, analyst says

Beacon Securities analyst Russell Stanley said Texas is “getting bigger for cannabis operators” after the state’s Department of Public Safety… [Read More]

2 days ago

Bank of Nova Scotia is the cheapest bank stock, this analyst says

RBC Dominion Securities analyst Darko Mihelic said Bank of Nova Scotia’s (Bank of Nova Scotia Stock Quote, Chart, News, Analysts,… [Read More]

2 days ago

This analyst just raised his price target on Marvell Technology

Marvell Technology (Marvell Technology Stock Quote, Chart, News, Analysts, Financials NASDAQ:MRVL) reported largely in-line fiscal third-quarter results and offered longer-term… [Read More]

3 days ago

Is Curaleaf still a buy?

Beacon Securities analyst Russell Stanley maintained his “Buy” rating and C$5.00 price target on Curaleaf Holdings (Curaleaf Holdings Stock Quote,… [Read More]

3 days ago